Premium
Application of HIF‐1α by gene therapy enhances angiogenesis and osteogenesis in alveolar bone defect regeneration
Author(s) -
Zhang Yang,
Huang Jiao,
Wang Chao,
Zhang Yan,
Hu Changhong,
Li Guangyue,
Xu Ling
Publication year - 2016
Publication title -
the journal of gene medicine
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 0.689
H-Index - 91
eISSN - 1521-2254
pISSN - 1099-498X
DOI - 10.1002/jgm.2876
Subject(s) - angiogenesis , gelatin , dental alveolus , genetic enhancement , regeneration (biology) , chemistry , immunohistochemistry , tissue engineering , in vivo , pathology , biomedical engineering , microbiology and biotechnology , medicine , gene , biology , dentistry , cancer research , biochemistry
Background A successful clinical outcome for implanted tissue‐engineered bone is dependent on the establishment of a functional vascular network. Gene‐enhanced tissue engineering represents a promising approach for vascularization and osteogenesis. In the present study, we tested the angiogenesis and osteogenesis efficacy of gelatin as the scaffold carrier in combination with a virus encoding the HIF‐1α gene in a rat alveolar bone defect model. Methods Three groups of 10 rats each were either left untreated, treated with adenovirus encoding hypoxia‐inducible factor‐1α (AdHIF‐1α)/gelatin sponge or treated with gelatin sponge with adenovirus encoding red fluorescence protein, respectively. At 4 weeks, all samples were determined by micro‐computed tomography, histological analyses and immunohistochemical studies. Results Scaffolds loaded with AdHIF‐1α were able to sustain the release of AdHIF‐1α for up to 21 days and alveolar bone defects treated with scaffolds containing AdHIF‐1α significantly induced new bone and new vessel formation in vivo . Conclusions Overexpression of HIF‐1α by gene therapy may be a useful method for enhancing alveolar bone defect osteogenesis and angiogenesis. Copyright © 2016 John Wiley & Sons, Ltd.